Chronic treatment with Parlodel LAR(®) of patients with prolactin-secreting tumours. Different responsiveness of micro- and macroprolactinomas

C. Maraschini, M. Moro, A. Masala, P. Toja, S. Alagna, A. Brunani, P. P. Rovasio, A. Ginanni, I. Lancranjan, F. Cavagnini

Research output: Contribution to journalArticle

Abstract

Forty-one patients with prolactinoma (25 micro-, 16 macroprolactinomas) were treated with a long-acting injectable preparation of bromocriptine (Parlodel LAR(®), Sandoz), 25-100 mg (mostly 50 mg) im every 4-8 weeks for as long as 43 months (median 19 months). The first injection caused a prompt fall of plasma PRL which reached its nadir value after 3 days. Thereafter, hormone levels remained well below initial values for 4 weeks or longer, though with the tendency, more pronounced in microprolactinoma patients, to rise again toward baseline. The prevalence of PRL normalization was greater in the macro- than in the microprolactinoma group. By repeated injections plasma PRL could be kept close to or within the normal limits in most of the patients. However, the extent of PRL inhibition was significantly greater in macro- than in microprolactinoma patients (p

Original languageEnglish
Pages (from-to)494-501
Number of pages8
JournalActa Endocrinologica
Volume125
Issue number5
Publication statusPublished - 1991

    Fingerprint

ASJC Scopus subject areas

  • Endocrinology

Cite this

Maraschini, C., Moro, M., Masala, A., Toja, P., Alagna, S., Brunani, A., Rovasio, P. P., Ginanni, A., Lancranjan, I., & Cavagnini, F. (1991). Chronic treatment with Parlodel LAR(®) of patients with prolactin-secreting tumours. Different responsiveness of micro- and macroprolactinomas. Acta Endocrinologica, 125(5), 494-501.